Tamura Jocelyn K, Carvalho Isabelle P, Leanna Lui M W, Feng Jia Nuo, Rosenblat Joshua D, Mansur Rodrigo, Lee Yena, Cha Danielle S, Teopiz Kayla, Ahmad Zara, Nasri Flora, Kim Jiin, McIntyre Roger S
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
CNS Spectr. 2021 Jan 28:1-22. doi: 10.1017/S1092852921000092.
Cognitive impairment is common in bipolar disorder and is emerging as a therapeutic target to enhance quality of life and function. A systematic search was conducted on PubMed, PsycInfo, Cochrane, clinicaltrials.gov, and Embase databases for blinded or open-label randomized controlled trials evaluating the pro-cognitive effects of pharmacological, neurostimulation, or psychological interventions for bipolar disorder. Twenty-two trials were identified, evaluating a total of 16 different pro-cognitive interventions. The methodological quality of the identified trials were assessed using the Cochrane Risk of Bias tool. Currently, no intervention (i.e., pharmacologic, neurostimulation, cognitive remediation) has demonstrated robust and independent pro-cognitive effects in adults with bipolar disorder. Findings are preliminary and methodological limitations limit the interpretation of results. Methodological considerations including, but not limited to, the enrichment with populations with pre-treatment cognitive impairment, as well as the inclusion of individuals who are in remission are encouraged. Future trials may also consider targeting interventions to specific cognitive subgroups and the use of biomarkers of cognitive function.
认知障碍在双相情感障碍中很常见,并且正逐渐成为提高生活质量和功能的治疗靶点。我们在PubMed、PsycInfo、Cochrane、clinicaltrials.gov和Embase数据库中进行了系统检索,以查找评估药物、神经刺激或心理干预对双相情感障碍的促认知作用的盲法或开放标签随机对照试验。共识别出22项试验,评估了总共16种不同的促认知干预措施。使用Cochrane偏倚风险工具评估所识别试验的方法学质量。目前,尚无干预措施(即药物、神经刺激、认知康复)在双相情感障碍成年患者中显示出强大且独立的促认知作用。研究结果是初步的,方法学上的局限性限制了对结果的解释。鼓励开展包括但不限于纳入治疗前有认知障碍人群以及缓解期个体的方法学考量。未来的试验也可考虑针对特定认知亚组进行干预,并使用认知功能生物标志物。